深圳开立生物医疗科技股份有限公司 2023 年限制性股票激励计划授予激励对象名单（授予日） | 人员 | 国籍 | 获授的限制性 | 占本激励计划授予 限制性股票总数的 | 占目前总 股本的比 | | --- | --- | --- | --- | --- | | | | 股票数量（股） | | | | | | | 比例 | 例 | | YANG MEI | 加拿大 | 1,597,000 | 48.48% | 0.37% | | Helga Schemm | 德国 | 107,100 | 3.25% | 0.02% | | 微创外科业务团队员工及董事 会认为应当激励的其他人员 | 中国 | 1,589,900 | 48.27% | 0.37% | | （共 32 人） | | | | | | 合计 | | 3,294,000 | 100.00% | 0.76% | 一、限制性股票激励计划分配情况表 注：上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致，下同。 二、微创外科业务团队员工及董事会认为应当激励的其他人员名单 2023 年 9 月 21 日 | 序号 | 姓名 | 职务 | | - ...

证券代码：300633 证券简称：开立医疗 公告编号：2023-050 深圳开立生物医疗科技股份有限公司 经公司监事会认真审核后认为： 第三届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2023 年 9 月 20 日，深圳开立生物医疗科技股份限公司（以下简称"公司"） 第三届监事会第十四次会议在深圳市光明区光电北路 368 号开立医疗大厦一楼 会议室召开。本次会议由监事会主席陈欣主持。应出席监事 3 名，实际出席监事 3 名。符合《公司章程》规定的法定人数，本次监事会会议决议合法有效。 二、监事会会议审议情况 1、审议通过《关于向激励对象授予限制性股票的议案》 （1）公司不存在《上市公司股权激励管理办法》（以下简称"《管理办法》"） 等法律、法规和规范性文件规定的禁止实施股权激励计划的情形，公司具备实施 股权激励计划的主体资格； 本激励计划授予的激励对象具备《公司法》、《证券法》等法律、法规和规范 性文件规定的任职资格，符合《管理办法》及《深圳证券交易所创业板股票上市 规则》规定的激励对象条件，符合公司《 ...

北京市中伦（深圳）律师事务所 关于深圳开立生物医疗科技股份有限公司 2023年限制性股票激励计划首次授予相关事项的 法律意见书 二〇二三年九月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 释义 在本法律意见书中，除非另有说明，以下简称或用语具有如下含义： | 公司/开立医疗 | 指 | 深圳开立生物医疗科技股份有限公司 | | --- | --- | --- | | 本激励计划、本 | | | | 次限制性股票 | 指 | 开立医疗 2023 年限制性股票激励计划 | | 激励计划 | ...

北京市中伦（深圳）律师事务所 关于深圳开立生物医疗科技股份有限公司 2023年第一次临时股东大会的 法律意见书 二〇二三年九月 本所律师根据《股东大会规则》的要求，按照律师行业公认的业务标准、道 德规范和勤勉尽责的精神，参加了本次股东大会现场会议，并对公司提供的相关 文件和有关事实进行了核查和验证，现出具如下法律意见： 一、关于本次股东大会的召集、通知和召开程序 （一）本次股东大会的召集人 - 1 - 广东省深圳市福田区益田路 6003 号荣超中心 A 栋 8-10 层 邮编：518026 8-10/F, Tower A, Rongchao Tower, 6003 Yitian Road, Futian District, Shenzhen, Guangdong 518026, P.R. China 电话/Tel : +86 755 3325 6666 传真/Fax : +86 755 3320 6888/6889 www.zhonglun.com 北京市中伦（深圳）律师事务所 关于深圳开立生物医疗科技股份有限公司 2023 年第一次临时股东大会的 法律意见书 致：深圳开立生物医疗科技股份有限公司 根据《中华 ...

证券代码：300633 证券简称：开立医疗 公告编号：2023-046 深圳开立生物医疗科技股份有限公司 关于 2023 年限制性股票激励计划内幕信息知情人及激励对象 买卖公司股票情况的自查报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳开立医疗股份有限公司（以下简称"公司"）于 2023 年 8 月 21 日召开 第三届董事会第十三次会议及第三届监事会第十三次会议，审议通过了《关于 公司<2023 年限制性股票激励计划（草案）及其摘要>的议案》等议案，并于 2023 年 8 月 23 日在巨潮资讯网（http://www.cninfo.com.cn）上披露相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深圳证 券交易所创业板上市公司自律监管指南第 1 号——业务办理》（以下简称"《自 律监管指南》"）等相关法律、法规的规定，通过向中国证券登记结算有限公司 深圳分公司查询，公司对 2023 年限制性股票激励计划（以下简称"本次激励计 划"）内幕信息知情人及激励对象在本次激励计划草案公告前 6 个月内（即 2023 年 2 ...

证券代码：300633 证券简称：开立医疗 公告编号：2023-047 深圳开立生物医疗科技股份有限公司 2023 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议的召开和出席情况 （一）召开情况 1、召开时间： （1）现场会议：2023 年 9 月 7 日（星期四）下午 14:30 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的时间为 2023 年 9 月 7 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳证券交易所 互联网系统投票的具体时间为 2023 年 9 月 7 日 9:15-15:00 期间的任意时间。 2、现场会议召开地点：深圳市光明区光电北路 368 号开立医疗大厦一楼 121 会议室 3、召开方式：现场表决与网络投票相结合的方式 4、召集人：深圳开立生物医疗科技股份有限公司董事会 5、主持人：董事长陈志强先生 3、北京市中伦（深圳）律师事务所的见证律师 ...

深圳开立生物医疗科技股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳开立生物医疗科技股份有限公司（以下简称"公司"）近日收到公司 控股股东之一吴坤祥先生的通知，获悉其将所持有的公司部分股份办理了解除 质押及再质押手续，具体事项如下： 一、本次股东股份质押的基本情况 证券代码：300633 证券简称：开立医疗 公告编号：2023-044 截至本公告披露日，公司控股股东陈志强先生、吴坤祥先生（一致行动 人）所持公司股份累计质押情况如下： | 股东名称 | 持股数量 | 持股比例 | 累计质押数 | 占其所持股 | 占公司总股 | | --- | --- | --- | --- | --- | --- | | | | | 量 | 份比例 | 本比例 | | 陈志强 | 95,725,200 | 22.23% | 10,500,000 | 10.97% | 2.44% | | 吴坤祥 | 95,725,200 | 22.23% | 8,100,000 | 8.46% | 1.88% | | 合计 | 191 ...

证券代码：300633 证券简称：开立医疗 公告编号：2023-045 深圳开立生物医疗科技股份有限公司监事会 关于公司 2023 年限制性股票激励计划激励对象名单 的核查意见及公示情况说明 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 公司监事会核查了本次拟激励对象的名单、身份证件、拟激励对象与公司或 子公司签订的劳动合同（或聘用合同）、拟激励对象在公司或子公司担任的职务 及其任职情况等。 二、监事会的核查意见 监事会根据《管理办法》、《自律监管指南》等有关法律、法规、规范性文件 的规定，对本次激励计划激励对象名单进行了核查，并发表核查意见如下： 1、本次激励计划激励对象为公司微创外科业务团队员工（包含外籍员工） 及董事会认为应当激励的其他人员，均为公司或子公司正式在职员工。本计划激 励对象不包括独立董事、监事，也不包括单独或合计持有公司 5%以上股份的股 东或实际控制人及其配偶、父母、子女。 一、公示情况及核查方式 深圳开立生物医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 21 日召开第三届董事会第十三次会议、第三届监事会第十三次会议 ...

长城证券股份有限公司 | 项 目 | 工作内容 | | --- | --- | | 1．公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限 于防止关联方占用公司资源的制度、募集资金管理 | 是 | | 制度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3．募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月 1 次 | | （2）公司募集资金项目进展是否与信息披露文件 | 是 | | 一致 | | | 4．公司治理督导情况 | | | （1）列席公司股东大会次数 | 次 0 | | （2）列席公司董事会次数 | 0 次 | | （3）列席公司监事会次数 | 0 次 | | 5．现场检查情况 | | | 项 目 | 工作内容 | | --- | --- | | （1）现场检查次数 | 1 次，对募集资金存放与使用情况进行 | | | 了核 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 1,043,339,390.90, representing a 24.87% increase compared to CNY 835,528,794.61 in the same period last year[17]. - The net profit attributable to shareholders for the first half of 2023 was CNY 273,059,845.78, a 56.18% increase from CNY 174,835,885.10 in the previous year[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 273,092,726.63, reflecting a 67.97% increase from CNY 162,586,812.07 in the same period last year[17]. - The basic earnings per share for the first half of 2023 was CNY 0.6382, up 56.19% from CNY 0.4086 in the previous year[17]. - The diluted earnings per share for the first half of 2023 was CNY 0.6349, an increase of 55.38% compared to CNY 0.4086 in the same period last year[17]. - The company's revenue for the first half of 2023 showed steady growth, with net profit attributable to shareholders significantly increasing, aligning with the company's initial plans[35]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2023, representing a 25% year-over-year growth[48]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2023, representing a year-over-year growth of 20%[49]. Research and Development - The company's R&D expenses accounted for nearly 20% of its operating revenue during the reporting period[2]. - The company is focused on the development of new products and technologies to enhance its market position[2]. - The company is committed to continuous R&D investment to maintain its competitive edge and respond quickly to market demands[34]. - The company has over 600 R&D personnel, with more than 40% holding master's degrees or higher, and has received multiple national and provincial recognitions for its innovation capabilities[61]. - R&D expenses for 2020, 2021, and 2022 were CNY 237.42 million, CNY 263.06 million, and CNY 328.96 million, representing 20.41%, 18.21%, and 18.66% of total revenue respectively[61]. - The company is investing in R&D for advanced imaging technologies, with a budget allocation of 200 million RMB for 2023, aiming to innovate and expand its product line[48]. Market Position and Strategy - The medical device market is highly competitive, with numerous participants, and the company must maintain its competitive advantages to avoid market elimination[3]. - The company has established a strong competitive advantage in the international medical device market, particularly in ultrasound and endoscope sectors[25]. - The company continues to focus on expanding its product offerings and market presence, particularly in the ultrasound diagnostic equipment sector[17]. - The company aims to contribute to the rise of domestic medical devices by developing high-end medical equipment with independent intellectual property rights[25]. - The company is focusing on expanding its multi-product strategy, transitioning from diagnostic to "diagnostic + treatment" solutions[32]. - The company is actively pursuing new strategies for market expansion, leveraging its innovative product pipeline to capture growth opportunities in the medical device sector[41][42]. Product Development and Innovation - The company has developed a comprehensive range of ultrasound products, including high-end, mid-range, and low-end devices, meeting diverse clinical application needs across various fields[27]. - The high-end ultrasound products S60 and P60 series have received high recognition from experts in top-tier hospitals, particularly excelling in obstetrics and gynecology compared to imported counterparts[27]. - The company has successfully obtained NMPA Class III medical device registration for its intravascular ultrasound diagnostic equipment and disposable intravascular ultrasound diagnostic catheters, becoming the only domestic ultrasound manufacturer with such capabilities[31]. - The new ultra-high-end ultrasound platform received CE (MDR) certification in December 2022, expected to enhance market competitiveness and brand influence upon launch[27]. - The company has expanded its product line in the endoscope sector, including HD350, HD400, HD500, and HD550 series, covering high, mid, and low-end markets[28]. - The introduction of the SFI imaging technology and the combination with the HD-550 system provides a complete solution for early diagnosis and treatment of diseases[28]. - The company has launched the ProPet series for veterinary ultrasound applications, further broadening its ultrasound product market[32]. - The company’s ultrasound products have achieved significant advancements, with a complete range of high, mid, and low-end products developed over 20 years[32]. Financial Position - Total assets at the end of the reporting period were CNY 3,692,742,172.90, a 4.19% increase from CNY 3,544,216,145.59 at the end of the previous year[17]. - The net assets attributable to shareholders at the end of the reporting period were CNY 3,000,049,043.36, reflecting a 9.50% increase from CNY 2,739,802,619.18 at the end of the previous year[17]. - The weighted average return on equity for the first half of 2023 was 9.48%, an increase of 2.37% from 7.11% in the previous year[17]. - The company's gross profit margin has improved due to an increase in the proportion of high-end products sold, while the ratio of operating expenses to revenue has decreased[37]. - The company reported a total investment of ¥27,630,500.99 during the reporting period, a decrease of 32.51% from ¥40,941,025.43 in the same period last year[79]. - The company has ongoing major non-equity investments, including the construction of a medical device industrial base with an investment of ¥1,139,899.51, which is 98.46% complete[81]. Risks and Challenges - The company faces risks related to overseas sales, including currency fluctuations and geopolitical tensions, which could adversely affect its international business[2]. - The company acknowledges the potential impact of healthcare policy changes on market pricing and procurement processes[4]. - The company continues to face various risks, with specific measures outlined in the report[101]. - The company has not experienced any significant litigation or arbitration matters during the reporting period[112]. - The company has not engaged in any major related party transactions during the reporting period[114]. Corporate Governance and Shareholder Information - The company does not plan to distribute cash dividends or issue bonus shares[6]. - The annual general meeting held on May 10, 2023, had an investor participation rate of 57.44%[105]. - The company has not encountered any issues regarding the use and disclosure of raised funds[88]. - The company has not made any capital increases from capital reserves during the reporting period[106]. - The company has no significant changes in the conditions affecting the performance of contracts during the reporting period[118]. - The company has no major risks of contract non-performance during the reporting period[118].